![](https://webarchive.library.unt.edu/eot2008/20090509161410im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509161410im_/http://www.cancer.gov/images/spacer.gif)
MLN2704 An immunoconjugate that consists of a humanized monoclonal antibody (MLN591), directed against prostate-specific membrane antigen linked to a maytansinoid (DM1). The monoclonal antibody moiety of MLN2704 binds to tumor cells expressing prostate-specific membrane antigen; MLN274 is then internalized into the tumor cell where the DM1 maytansinoid moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, resulting in a disruption of microtubule activity and cell division, and cell death. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509161410im_/http://www.cancer.gov/images/spacer.gif)
Synonyms: | ![](https://webarchive.library.unt.edu/eot2008/20090509161410im_/http://www.cancer.gov/images/spacer.gif) | DM1-conjugated monoclonal antibody MLN591 maytansinoid -1 conjugated with MLN591 monoclonal antibody | | ![](https://webarchive.library.unt.edu/eot2008/20090509161410im_/http://www.cancer.gov/images/spacer.gif) | Code name: | ![](https://webarchive.library.unt.edu/eot2008/20090509161410im_/http://www.cancer.gov/images/spacer.gif) | MLN591DM1 | | ![](https://webarchive.library.unt.edu/eot2008/20090509161410im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509161410im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509161410im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509161410im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509161410im_/http://www.cancer.gov/images/spacer.gif) |